GRAL · GRAIL, Inc.
$68.56
-2.58 (-3.63%)
At close · Jul 31
Market Cap
$2.94B
Shares
42.92M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$68.56
Open$71.54
Day$67.20–71.57
52W$29.95–118.84
Avg vol 30d564K
Short int7.7M · 18.0% float · 15.5d
Short vol57%
Last earningsMay 5, 2026
DataJun 2024–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 3, 2026
Est · unconfirmed
· this week
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−8%
below
Price vs 50-day avg
+3%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
43%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
−31%
trailing
YTD return
−20%
this year
Relative strength
−40%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $67 › 200d $74 — 200d above 50d
Institutional flow
Distributing
122 of 370 funds reported for Jun 30 · net -162.5K sh shares · +18 new
Insider flow
Distributing
Net -$91.1K over 90 days · 100% sells
Short interest
Falling
18.02% of float · ▼ -0.2% MoM · 15.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
370 holders — mid 2-yr range
Squeeze score
82
high risk · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
EPS growth
+83%
Y/Y
Free cash flow
$-299.9M
Balance sheet
$249.7M
net cash
Quant / Vol
risk profile
Volatility
98%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Sep 30, 2025
Cash burn
· full year 2025
up to $290M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−8%
Bearish
Price vs 50-day avg
+3%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
43%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $67 › 200d $74 — 200d above 50d
Institutional flow
Distributing
122 of 370 funds reported for Jun 30 · net -162.5K sh shares · +18 new
Insider flow
Distributing
Net -$91.1K over 90 days · 100% sells
Short interest
Falling
18.02% of float · ▼ -0.2% MoM · 15.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
370 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $30
Now $69 · 43%
52-wk high $119
vs 200-day avg -8%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$79.9M | Q1 2026 | — |
|
|
|||
| Adjusted gross profit non-GAAP | $19.7M | Q1 2026 | — |
|
|
|||
| Cash position | $823.1M | Q1 2026 | — |
| Galleri Tests Sold | 185,000 | full year 2025 | — |
| >800k In market with Galleri MCED test | 800K | as of January 12, 2026 | — |
| Cash burn | $274M | FY2025 | — |
| Commercial Galleri® tests sold to-date | 475K | as of January 12, 2026 | — |
| Prescriber growth over 2024 | 30% | as of December 31, 2025 | — |
| Test capacity at RTP site | 1M | as of January 12, 2026 | — |
| Total Galleri volume | 185K | FY2025 | — |
| Total Galleri volume growth over 2024 | 35% | FY2025 | — |
| Unique prescribers since launch | 17K | as of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRAL
this stock
GRAIL, Inc.
|
$2.94B | -19.9% | +17.2% | — | 18.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$212.35B | -0.8% | +0.4% | 30.9 | 1.4% |
|
DHR
Danaher Corp /De/
|
$137.07B | -14.5% | +8.5% | 34.6 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.10B | -17.4% | +10.4% | 41.1 | 2.7% |
|
IQV
Iqvia Holdings Inc.
|
$39.22B | +4.3% | +41.6% | 29.2 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRAL | +1.1% | -0.8% | -31.5% | +0.4% | -19.9% |
| SPY | +1.1% | +0.3% | +8.2% | +0.0% | +9.6% |
| vs SPY | 0.0% | -1.1% | -39.7% | +0.4% | -29.5% |
Key facts
CIK
1699031
CUSIP
384747101
13F (30d)
113 filings
106 filers
Visit website
Investor relations